More about

Rituximab

News
March 09, 2023
2 min read
Save

Rituximab improves long-term skin, lung outcomes in systemic sclerosis

Rituximab improves long-term skin, lung outcomes in systemic sclerosis

Rituximab was associated with significant improvements in both skin and lung parameters over long-term follow-up in a cohort of patients with systemic sclerosis, according to a study.

News
February 17, 2023
1 min read
Save

Top in rheumatology: COVID-19 vaccination in rituximab users; familial Mediterranean fever

Top in rheumatology: COVID-19 vaccination in rituximab users; familial Mediterranean fever

Research has shown that breakthrough SARS-CoV-2 infections are common among patients using rituximab. However, a new study found that few rituximab users who are fully vaccinated against COVID-19 develop severe symptoms.

News
February 09, 2023
2 min read
Save

Vaccination reduces risk for severe COVID-19 in patients using rituximab

Vaccination reduces risk for severe COVID-19 in patients using rituximab

Although the breakthrough infection rate has been high in patients using rituximab during the later stages of the COVID-19 pandemic, a small proportion of those who are fully vaccinated develop severe outcomes, according to data.

News
February 01, 2023
1 min read
Save

Two treatment regimens improve quality of life among patients with DLBCL

NEW ORLEANS — Health-related quality of life in patients with diffuse large B-cell lymphoma improved in a comparison of two therapy regimens.

News
January 19, 2023
2 min read
Save

Long-term data needed to determine cost efficacy of new DLBCL treatments

Long-term data needed to determine cost efficacy of new DLBCL treatments

NEW ORLEANS — Cost efficacy of polatuzumab vedotin added to traditional treatments for diffuse large B-cell lymphoma in the front-line requires long-term PFS data, according to a poster presented at ASH Annual Meeting and Exhibition.

News
January 18, 2023
2 min read
Save

Rituximab superior to cyclophosphamide in GPA remission induction

Rituximab superior to cyclophosphamide in GPA remission induction

In patients with granulomatosis with polyangiitis, those who start induction therapy with rituximab are more likely to achieve remission compared with those who begin cyclophosphamide, according to data published in JAMA Network Open.

News
December 29, 2022
1 min read
Save

COVID-19 vaccines, boosters recommended for MS patients taking rituximab

COVID-19 vaccines, boosters recommended for MS patients taking rituximab

People with MS who are being treated with rituximab are strongly encouraged to receive mRNA SARS-CoV-2 vaccines and booster doses more than 6 months after their last rituximab infusion, researchers reported in JAMA Network Open.

News
December 29, 2022
2 min read
Save

Rituximab may prevent long-term comorbidities in treatment of pemphigus

Rituximab may prevent long-term comorbidities in treatment of pemphigus

Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but similar in survival rate, compared with other adjuvant agents in the treatment of pemphigus, according to a study.

News
December 22, 2022
4 min read
Save

Consensus statement on thyroid eye disease focuses on new therapies, individualized care

Consensus statement on thyroid eye disease focuses on new therapies, individualized care

Individualized care and patient satisfaction are among the areas of emphasis in a new consensus statement on management of thyroid eye disease.

News
November 22, 2022
2 min read
Save

Double-dose pneumococcal vaccine boosts immune response in patients with AAV on rituximab

Double-dose pneumococcal vaccine boosts immune response in patients with AAV on rituximab

PHILADELPHIA — An initial double dose of pneumococcal vaccine improves immune response against pneumococcal pneumonia in patients with ANCA-associated vasculitis treated with rituximab, according to data presented at ACR Convergence 2022.

View more